Equities

Amgen Inc

0R0T:LSE

Amgen Inc

  • Price (USD)380.08
  • Today's Change13.52 / 3.69%
  • Shares traded2.73k
  • 1 Year change26.48%
  • Beta0.4591
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

  • Revenue in USD (TTM)36.75bn
  • Net income in USD7.71bn
  • Incorporated1986
  • Employees28.00k
  • Location
    Amgen IncOne Amgen Center DriveTHOUSAND OAKS 91320-1799United StatesUSA
  • Phone+1 (805) 447-1000Fax+1 (302) 636-5454
  • Websitehttps://www.amgen.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0R0T:LSE since
announced		Transaction
value
Dark Blue Therapeutics LtdDeal completed06 Jan 202606 Jan 2026Deal completed18.51%840.00m
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.